Phase 3CompletedAge-related condition
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
A Phase 3, Twenty-Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause
- Sponsor
- Noven Therapeutics (Industry)
- Enrollment
- 570 enrolled
- Conditions
- Hot Flashes
- Interventions
- Brisdelle (paroxetine mesylate); Placebo capsules
- Ages
- adults, older adults
- Registry
- NCT01101841
Full record on ClinicalTrials.gov
From the registry
To assess the safety and efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause
Primary outcomes
- Mean Change From Baseline in Hot Flash Frequency at Week 4 and Week 12.
- Mean Change From Baseline in Hot Flash Severity at Week 4 and Week 12.
History
Last registry update
Results first posted
Study completion
Primary completion
Registered
Started